Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (7 quarters reported)
$294M in Q4 2024 → $498M now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Rapport Therapeutics, Inc. | 52.5% | Trimmed 12% | 6,280,525 | $262M |
| Septerna, Inc. | 41.8% | Unchanged | 6,215,591 | $208M |
| Maze Therapeutics, Inc. | 5.7% | Unchanged | 950,800 | $28.4M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 6 quarters.
quarter ended June 30, 2026 · filed August 10, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Rapport Therapeutics, Inc. | Trimmed | −854,708 | −$35.6M | 52.5% |
quarter ended March 31, 2026 · filed May 07, 2026
No position changes this quarter.
quarter ended December 31, 2025 · filed February 13, 2026
No position changes this quarter.
quarter ended September 30, 2025 · filed November 13, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Cargo Therapeutics, Inc. | Exited | −1,737,216 | −$7.16M | — |
quarter ended June 30, 2025 · filed August 08, 2025
No position changes this quarter.
quarter ended March 31, 2025 · filed May 09, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Maze Therapeutics, Inc. | New | +950,800 | +$10.5M | 8.4% |
Loading...
